• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Psyence Biomedical Ltd.

    11/12/24 1:45:06 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBM alert in real time by email
    SC 13G 1 sch13g.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
     
    (Amendment No. )


    Psyence Biomedical Ltd.
    (Name of Issuer)
     
    Common Shares, no par value
    (Title of Class of Securities)
     
    74449F100
    (CUSIP Number)
     
    September 30, 2024
    (Date of Event Which Requires Filing of the Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:


    ☒
    Rule 13d-1(b)

    ☐
    Rule 13d-1(c)

    ☐
    Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Page 1 of 5

    Cusip No. 74449F100
     
    Page 2 of 5 Pages
     
     
    1.
     
    NAME OF REPORTING PERSONS
     
    AdvisorShares Trust

     
    2.
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)  ☐    
    (b)  ☐    
     
     
    3.
     
    SEC USE ONLY
     
    4.
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
     NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
     
    5.

     SOLE VOTING POWER
     1,232,376
     
    6.

     SHARED VOTING POWER
     0
     
    7.

     SOLE DISPOSITIVE POWER
     1,232,376
     
    8.

     SHARED DISPOSITIVE POWER
     0
     
    9.

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     1,232,376
     
    10.

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     ☐
     
    11.

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     7.38%
     
    12.

     TYPE OF REPORTING PERSON (See Instructions)
     IV
             

    Page 2 of 5

    Cusip No. 74449F100
     
    Page 3 of 5 Pages

    Item 1(a).
    Name of Issuer:  Psyence Biomedical Ltd.

    Item 1(b).
    Address of Issuer’s Principal Executive Offices:

    121 Richmond Street West
    Penthouse Suite 1300
    Toronto, Ontario M5H 2K1
    Canada

    Item 2(a).
    Name of Person Filing: AdvisorShares Trust

    Item 2(b).
    Address of Principal Business Office or, if none, Residence:

    4800 Montgomery Lane, Suite 150
    Bethesda, Maryland 20814

    Item 2(c).
    Citizenship: Delaware

    Item 2(d).
    Title of Class of Securities:  Common Shares, no par value

    Item 2(e).
    CUSIP Number: 74449F100

    Item 3.
    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     
    (a)
    [  ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C 78o);
           
     
    (b)
    [  ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C 78c);
           
     
    (c)
    [  ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C 78c);
           
     
    (d)
    [X]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
           
     
    (e)
    [ ]
    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
           
     
    (f)
    [  ]
    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
     
    (g)
    [  ]
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
           
     
    (h)
    [  ]
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
     
    (i)
    [  ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
     
    (j)
    [  ]
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
           
     
    (k)
    [   ]
    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
    _______________
     
    Page 3 of 5

    Cusip No. 74449F100
     
    Page 4 of 5 Pages

    Item 4.
    Ownership:

    Provide the following information regarding the aggregate number and percentage of class of securities of the issuer identified in Item 1.


    (a)
    Amount beneficially owned:  1,232,376


    (b)
    Percent of Class: 7.38%


    (c)
    Number of shares as to which such person has:


    (i)
    sole power to vote or to direct the vote: 1,232,376


    (ii)
    shared power to vote or to direct the vote: 0


    (iii)
    sole power to dispose or to direct the disposition of: 1,232,376


    (iv)
    shared power to dispose or to direct the disposition of: 0

    Item 5.
    Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [  ].

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person:

    Not Applicable

    Item 7.
    Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not Applicable

    Item 8.
    Identification and Classification of Members of the Group:

    Not Applicable

    Item 9.
    Notice of Dissolution of Group:

    Not Applicable


    Page 4 of 5

    Cusip No. 74449F100
     
    Page 5 of 5 Pages

    Item 10. Certifications:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    November 12, 2024
     
    (Date)
       
     
    /s/ Stefanie Little
     
    (Signature)
       
     
    Stefanie Little – Chief Compliance Officer
     
    Name and Title

     

    Page 5 of 5
    Get the next $PBM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PBM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PBM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

      Appointment adds significant clinical and scientific expertise in the field of psychedelic-based therapiesNew York, New York--(Newsfile Corp. - March 18, 2025) - Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it has expanded and further strengthened its Scientific Advisory Board (SAB) with the appointment of Dr. Dan J. Stein, a recognized leader in the field of psychopharmacology. He is the Professor and Chair of the Dept of Psychiatry and Mental Health at the University of Cape Town (UCT) and Director of the South African Medical Research Council (MRC) Unit on Risk & Resilience in Mental Disorders. Dr. Stein joins Dr. Albert Garcia-Romeu (Chair

      3/18/25 8:30:00 AM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

      NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it will work closely with Albert P. Garcia-Romeu, Ph.D., to chair and develop its newly created Scientific Advisory Board (SAB). Dr. Garcia-Romeu is a leading psychedelics researcher currently serving as Associate Professor in the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, as well as Associate Director, Johns Hopkins Center for Psychedelic and Consciousness Research and the Susan Hill Ward Professor in Psychedelics and Consciousness. He is a highly sought after speaker on the therapeutic potential of p

      2/26/25 8:00:00 AM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Psyence Biomed Announces Closing of $2.0 Million Private Placement

      NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,000,000 common shares (or pre-funded warrants in lieu thereof), series A common warrants to purchase up to 1,000,000 common shares and short-term series B common warrants to purchase up to 1,000,000 common shares at a purchase price of $2.00 per common share (or per pre-funded warrant in lieu thereof) and accompanying series A common warrant and short-term series B common warrant. The series A common warrants and short-term series B common warrants hav

      12/27/24 4:05:35 PM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Psyence Biomedical Ltd.

      SC 13G - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

      12/13/24 9:16:01 AM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

      SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

      12/9/24 1:36:43 PM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

      SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

      12/4/24 4:38:27 PM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBM
    SEC Filings

    See more
    • SEC Form 6-K filed by Psyence Biomedical Ltd.

      6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

      5/6/25 4:01:32 PM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Psyence Biomedical Ltd.

      6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

      4/23/25 4:26:27 PM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Psyence Biomedical Ltd.

      6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

      4/11/25 4:00:12 PM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBM
    Leadership Updates

    Live Leadership Updates

    See more
    • Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

      NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it will work closely with Albert P. Garcia-Romeu, Ph.D., to chair and develop its newly created Scientific Advisory Board (SAB). Dr. Garcia-Romeu is a leading psychedelics researcher currently serving as Associate Professor in the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, as well as Associate Director, Johns Hopkins Center for Psychedelic and Consciousness Research and the Susan Hill Ward Professor in Psychedelics and Consciousness. He is a highly sought after speaker on the therapeutic potential of p

      2/26/25 8:00:00 AM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

      NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced the voting results for each of the matters presented at the Company's annual and special meeting of shareholders held on November 12, 2024 (the "Meeting"). Shareholders were represented in person or by proxy at the meeting holding 21,877,200 common shares, representing approximately 43.5% of Psyence Biomed's 50,334,170 issued and outstanding common shares as of October 10, 2024, the record date for the Meeting. At the Meeting, a total of five resolutions (the "Resolutions" and each a "Resolution") were submitted to and approved by the Company's shareholder

      11/12/24 4:30:00 PM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

      Clairvoyant currently executing a fully randomized multi-country Phase IIb clinical trial evaluating a synthetic psilocybin candidate as a potential therapeutic for Alcohol Use Disorder (AUD) Topline data from the ongoing Phase IIb AUD study anticipated in early 2025 NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that the Company has entered into a conditional binding term sheet with privately-held Clairvoyant Therapeutics Inc ("Clairvoyant"), a clinical-stage developer of psilocybin-based therapeutics based in Canada, for the proposed acquisition by Psyence Biomed of 100% of the shareholdings

      9/6/24 7:30:00 AM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care